[1] UNDERBJERG L,SIKJAER T,MOSEKILDE L,et al. Pseudohypoparathyroidism-epidemiology,mortality and risk of complications[J]. Clin Endocrinol (Oxf),2016,84(6):904-911.
[2] TURAN S. Current nomenclature of pseudohypoparathyroidism:inactivating parathyroid hormone/parathyroid hormone-related protein signaling disorder[J]. J Clin Res Pediatr Endocrinol,2017,9(Suppl 2):58-68.
[3] ROMANET P,GALLUSO J,KAMENICKY P,et al. Somatotroph tumors and the epigenetic status of the GNAS locus[J]. Int J Mol Sci,2021,22(14):7570.
[4] LEMOS M C,THAKKER R V. GNAS mutations in pseudohypo-parathyroidism type 1a and related disorders[J]. Hum Mutat,2015 ,36(1):11-19.
[5] BASTEPE M. GNAS mutations and heterotopic ossification[J]. Bone,2018,109:80-85.
[6] LINGLART A,LEVINE M A,J?譈PPNER H. Pseudohypoparathyroidism[J]. Endocrinol Metab Clin North Am,2018,47(4):865-888.
[7] PICARD C,DECREQUY A,GUENET D,et al. Diagnosis and management of congenital hypothyroidism associated with pseudohypoparathyroidism[J]. Horm Res Paediatr,2015,83(2):111-117.
[8] 唐艳,黎涛,王覃,等.不同类型甲状旁腺功能减退症的临床特点[J].中华骨质疏松和骨矿盐疾病杂志,2017,9(10):462-468.
[9] ERTL D A,DE NANCLARES G P,J?譈PPNER H,et al. Recombinant growth hormone improves growth and adult height in patients with maternal inactivating GNAS mutations[J]. Eur J Endocrinol,2023, 189(1):123-131.
[10] MANTOVANI G,FERRANTE E,GIAVOLI C,et al. Recombinant human GH replacement therapy in children with pseudohypo-parathyroidism typeⅠa:first study on the effect on growth[J]. J Clin Endocrinol Metab,2010,95(11):5011-5017.